Search Results for "Dificid Medicare"
Original Source: Optimer’s Dificid Gets Medicare Payment “Add-On” For Hospital Patients
In a rare application of its Medicare “new technology add-on payments” policy to drugs, the Centers for Medicare and Medicaid Services announced it will supplement reimbursement to hospitals for the oral antibiotic Deficid and methotrexate toxici...
Matching Channels
None
Matching News
Optimer’s Dificid Gets Medicare Payment “Add-On” For Hospital Patients
In a rare application of its Medicare “new technology add-on payments” policy to drugs, the Centers for Medicare and Medicaid Services announced it will supplement reimbursement to hospitals for t...
Optimer Pharma Falls On Dificid Sales Concerns
NEW YORK (AP) — Shares of Optimer Pharmaceuticals tumbled 6 percent Tuesday as Wall Street weighed in on the company's marketing strategy and sales of its antibacterial drug Dificid.
CMS grants additional reimbursement for Dificid
Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) gained $1.40 (11%) to $14.29 on Thursday after CMS said it will provide hospitals with additional reimbursement payments beyond the predetermined standard ra...
Optimer Dificid wins approval from Australian regulatory body
Optimer Pharmaceuticals has announced the approval of Dificid (fidaxomicin) Tablets by the Australian regulatory body, the Therapeutic Goods Administration.
Steer Clear Of Optimer's Short And Long-Term Risks
ByPropThink: By Jake King The hope remains alive that Optimer (OPTR) will somehow power through a disappointing launch and increase prescription growth sufficiently to offset the 25% discount that t...
Optimer selling stake in Taiwan subsidiary for $60M
Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) plans to sell its 43.6% stake in Taiwan subsidiary Optimer Biotechnology Inc. to the subsidiary's other shareholders for $60 million. Optimer Biotechnology i...
Optimer's Dificid approved in Canada for Clostridium difficile infection
Health Canada approved Optimer Pharmaceuticals' Dificid (fidaxomicin) for the treatment of Clostridium difficile infection (CDI) in adults, making the San Diego company's antibiotic the first new dru...
Optimer's Dificid paves path for orals with CMS NTAP status
It took investors a few hours on 2 August to catch on to the significance of the win Optimer Pharmaceuticals scored with the US Centers for Medicare & Medicaid Services (CMS) in nabbing a new technol...
Matching PubMed Articles
Fidaxomicin (Dificid) for clostridium difficile infection.
Results of the Medicare Health Support disease-management pilot program.
In the Medicare Modernization Act of 2003, Congress required the Centers for Medicare and Medicaid Services to test the commercial disease-management model in the Medicare fee-for-service program.
The Zone Program Integrity Contractors (ZPICs) program is a government effort to eliminate fraud, waste, and abuse in Medicare. ZPICs perform a range of medical review, data analysis, and Medicare aud...
Flaws in the medicare readmission penalty.
Flaws in the Medicare Readmission Penalty This letter discusses unintended consequences of the Medicare readmission policy, which could have adverse effects on hospitals.
The insurance value of medicare.
Medicare should provide access to care and protection from catastrophic spending while not being so generous that beneficiaries overconsume low-value care, thus driving up costs. Setting cost sharing...
